Yasmin & YAZ Canada Settlement — $9.05 Million CAD, Up to $13,500 CAD

Pharmaceuticals · Claims Open

Current Status

Claims are open, and the deadline is April 9, 2027 at 11:59 p.m. Eastern Time; mailed claims count if postmarked by then. The courts in Ontario, Québec and Saskatchewan have all approved the settlement, the last on March 19, 2026, and court-approved notices of settlement approval were published in October 2026. Payments are made after the claims deadline and the administrator’s review.

What Changed Recently?

The national settlement, signed July 30, 2025, resolves three certified class actions: Schwoob v. Bayer Inc. in the Ontario Superior Court of Justice, Guindon v. Bayer Inc. in the Superior Court of Québec and Dembrowski v. Bayer Inc. in the Court of King’s Bench for Saskatchewan, along with 10 dormant proposed class actions in other provinces. The Québec court approved it on November 26, 2025, the Ontario court on November 27, 2025 and the Saskatchewan court on March 19, 2026. Court-approved notices of settlement approval dated October 8, 2026 opened the claims process, and class counsel announced it in a court-approved release on October 15, 2026.

The lawsuits alleged that Yasmin and YAZ carried a higher risk of blood clots and gallbladder disease than other oral contraceptives, that the risk was known to the defendants, and that it was not communicated in a timely or adequate way. Bayer denies the allegations, makes no admission as to their truth and denies any wrongdoing. The allegations and this page are not medical advice.

Who Qualifies?

The user class is everyone resident in Canada who was prescribed and took branded Yasmin or YAZ and was later diagnosed with arterial thromboembolism, venous thromboembolism or gallbladder disease. The use must fall within these windows:

• Start: December 10, 2004 for Yasmin, and January 6, 2009 for YAZ.

• End: November 30, 2011 for residents of Ontario and Québec, and October 4, 2016 for residents of the rest of Canada.

The settlement covers only Yasmin- and YAZ-branded pills distributed by Bayer in Canada, not generic versions. Family members with a derivative family-law claim through a user can also claim. People who opted out, parties to four listed individual lawsuits, and anyone who started a separate case against Bayer on the same subject are excluded.

How Much Can You Get?

The $9,050,000 CAD fund is all-inclusive. After $905,000 CAD for provincial health insurers and $6,000 CAD in representative-plaintiff honoraria, $8,139,000 CAD remains for class members, before administration costs and class counsel’s fees of 30% are deducted. Approved claims are paid pro rata by points, with a maximum for each injury:

• Venous thromboembolism (pulmonary embolism or deep vein thrombosis): 100 points, up to $9,000 CAD

• Arterial thromboembolism (ischemic stroke or heart attack): 50 points, up to $4,500 CAD

• Gallbladder disease or removal diagnosed within six months of taking Yasmin or YAZ: 5 points, up to $500 CAD

• Death from venous thromboembolism: 150 points, up to $13,500 CAD

• Death from arterial thromboembolism: 125 points, up to $11,250 CAD

• Family members: 10% of the primary claim’s points, shared if more than one family member claims for the same user

The value of a point depends on the money left after deductions and the total points claimed, so the amounts above are caps, not guaranteed payments. According to the Ontario court’s reasons, claimants do not have to prove that Yasmin or YAZ caused their condition, only that they took it during the window and were later diagnosed with a qualifying condition. Payments are made by cheque. Money left over goes to Women’s Health Collective Canada.